Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics

Arrowhead Pharmaceuticals, Inc. (ARWR): $28.68

0.02 (-0.07%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add ARWR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#321 of 363

in industry

ARWR Price/Volume Stats

Current price $28.68 52-week high $42.48
Prev. close $28.70 52-week low $20.67
Day low $28.04 Volume 214,252
Day high $29.08 Avg. volume 1,629,201
50-day MA $31.17 Dividend yield N/A
200-day MA $30.09 Market Cap 3.55B

ARWR Stock Price Chart Interactive Chart >

ARWR POWR Grades

  • Value is the dimension where ARWR ranks best; there it ranks ahead of 62.37% of US stocks.
  • ARWR's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • ARWR's current lowest rank is in the Growth metric (where it is better than 7.92% of US stocks).

ARWR Stock Summary

  • Of note is the ratio of ARROWHEAD PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 7.8% of US stocks have a lower such ratio.
  • With a price/sales ratio of 14.27, ARROWHEAD PHARMACEUTICALS INC has a higher such ratio than 92.37% of stocks in our set.
  • With a year-over-year growth in debt of 41.18%, ARROWHEAD PHARMACEUTICALS INC's debt growth rate surpasses 85.23% of about US stocks.
  • Stocks that are quantitatively similar to ARWR, based on their financial statements, market capitalization, and price volatility, are NTLA, IGMS, RNA, VIR, and DNLI.
  • Visit ARWR's SEC page to see the company's official filings. To visit the company's web site, go to arrowheadpharma.com.

ARWR Valuation Summary

  • ARWR's price/sales ratio is 13.7; this is 522.73% higher than that of the median Healthcare stock.
  • Over the past 237 months, ARWR's EV/EBIT ratio has gone NA NA.

Below are key valuation metrics over time for ARWR.

Stock Date P/S P/B P/E EV/EBIT
ARWR 2023-12-29 13.7 12.1 -16.0 -17.9
ARWR 2023-12-28 13.8 12.3 -16.2 -18.1
ARWR 2023-12-27 13.8 12.3 -16.2 -18.1
ARWR 2023-12-26 13.8 12.2 -16.2 -18.0
ARWR 2023-12-22 13.5 12.0 -15.9 -17.7
ARWR 2023-12-21 12.8 11.4 -15.1 -16.8

ARWR Growth Metrics

    Its 2 year price growth rate is now at -2.39%.
  • Its year over year price growth rate is now at -48.42%.
  • Its 3 year revenue growth rate is now at 177.9%.
ARWR's revenue has moved up $140,051,000 over the prior 15 months.

The table below shows ARWR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 278.338 -150.3 -154.516
2022-09-30 243.231 -136.131 -176.063
2022-06-30 249.939 -91.581 -153.926
2022-03-31 263.418 -52.344 -111.804
2021-12-31 144.424 148.799 -182.988
2021-09-30 138.287 171.224 -140.848

ARWR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARWR has a Quality Grade of C, ranking ahead of 55.82% of graded US stocks.
  • ARWR's asset turnover comes in at 0.171 -- ranking 211th of 682 Pharmaceutical Products stocks.
  • COLL, CRBP, and VBIV are the stocks whose asset turnover ratios are most correlated with ARWR.

The table below shows ARWR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.171 1 -0.460
2021-03-31 0.153 1 -0.385
2020-12-31 0.149 1 -0.363
2020-09-30 0.158 1 -0.397
2020-06-30 0.241 1 -0.218
2020-03-31 0.303 1 0.013

ARWR Price Target

For more insight on analysts targets of ARWR, see our ARWR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $87.92 Average Broker Recommendation 1.59 (Moderate Buy)

Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio


Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.


ARWR Latest News Stream


Event/Time News Detail
Loading, please wait...

ARWR Latest Social Stream


Loading social stream, please wait...

View Full ARWR Social Stream

Latest ARWR News From Around the Web

Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing.

Yahoo | December 24, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

PASADENA, Calif., December 21, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-st

Yahoo | December 21, 2023

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PASADENA, Calif., December 20, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT.

Yahoo | December 20, 2023

ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November 13, 2023, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced new clinical data for the Phase 2 SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) were presented at the American

Yahoo | December 5, 2023

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript November 29, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince […]

Yahoo | December 1, 2023

Read More 'ARWR' Stories Here

ARWR Price Returns

1-mo -7.97%
3-mo -6.27%
6-mo 6.74%
1-year 15.93%
3-year -53.25%
5-year 56.29%
YTD -6.27%
2023 -24.56%
2022 -38.82%
2021 -13.59%
2020 20.97%
2019 410.71%

Continue Researching ARWR

Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!